Compare SOPH & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOPH | CTNM |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 550.7M |
| IPO Year | 2021 | 2024 |
| Metric | SOPH | CTNM |
|---|---|---|
| Price | $8.79 | $17.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.50 | ★ $19.00 |
| AVG Volume (30 Days) | 474.9K | ★ 492.0K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.10 | $8.60 |
| 52 Week High | $8.84 | $17.35 |
| Indicator | SOPH | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 62.64 |
| Support Level | $4.63 | $13.65 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.44 | 0.98 |
| MACD | 0.09 | 0.19 |
| Stochastic Oscillator | 84.06 | 85.85 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.